RxDoctor Payments DataLook up a doctor →

Michael Overcash, PA

Physician Assistant · Charleston, SCNPI 1376520171

Payments from drug & device makers

$210,153in general payments, 2019–2025

Across 839 payments — averaging $250.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$94K
  • E.r. Squibb & Sons, L.L.C.$31K
  • Incyte Corporation$27K
  • Janssen Scientific Affairs, LLC$21K
  • Amgen$13K
  • Arcutis Biotherapeutics, Inc.$11K
  • plus $14K from 26 others

What the payments were for

  • Consulting fees$31,80315%
  • Speaking & faculty fees$145,46269%
  • Travel & lodging$14,2707%
  • Food & beverage$17,8178%
  • Education$8020%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$210,153 in reported general payments places this provider in the 95th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$405,109
Medicare patients
1,329
Services billed
9,511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast86$419,917
Skyrizi PenRisankizumab-Rzaa13$283,638
SkyriziRisankizumab-Rzaa13$274,823
TremfyaGuselkumab17$232,819
SiliqBrodalumab12$64,259
OpzeluraRuxolitinib Phosphate14$27,399
SeysaraSarecycline Hcl11$15,559
Clobetasol Propionate211$9,084
Tacrolimus33$4,511
Tretinoin48$2,772
Ivermectin12$2,736
Pimecrolimus14$2,110
Azelaic Acid11$1,734
Minoxidil168$1,625
Ammonium Lactate77$1,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$12,945$419,91786 claims
AbbVieSkyrizi$4,892$274,82313 claims
Johnson & JohnsonTremfya$93,884$232,81917 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCSiliq$107$64,25912 claims
Incyte CorporationOpzelura$26,879$27,39914 claims
Almirall LLCSeysara$124$15,55911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →